SCHEMBL26616365

SCHEMBL26616365

CC1CC2(C1)CC(NC(=O)c1ccc(F)c3ccn(Cc4ccc(N5CCOCC5)cc4)c13)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ PDE7A Q13946 1/20 0.38
▸ EGFR P00533 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ FLT3 P36888 2/20 0.36
▸ SRC P12931 1/20 0.36
▸ SCN9A Q15858 1/20 0.35
▸ P2RX3 P56373 1/20 0.35
▸ TYRO3 Q06418 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ GAS6 Q14393 1/20 0.35
▸ LIPG Q9Y5X9 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ STAT6 P42226 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21458170 0.91 PTGER4 (0.40) CNR1CNR2ROCK2PDE7AEGFR
SCHEMBL31203159 0.91 CNR2 (0.40) CNR1CNR2PDE7ASCN9ASMN1; SMN2
SCHEMBL26604251 0.86 CNR2 (0.42) CNR1CNR2ALDH1A1
SCHEMBL21485562 0.85 S1PR3 (0.40) CNR1CNR2P2RX3LIPG
SCHEMBL21481757 0.84 CNR1 (0.41) CNR1CNR2KMT2A
SCHEMBL21481826 0.84 CNR2 (0.43) CNR1CNR2
SCHEMBL21481783 0.84 CNR1 (0.39) CNR1CNR2PDE7AFLT3P2RX3
SCHEMBL21506748 0.83 CNR2 (0.40) CNR1CNR2
SCHEMBL21458116 0.82 ROCK2 (0.40) ROCK2PDE7AEGFRCDK2ALDH1A1
SCHEMBL26604285 0.82 CNR1 (0.38) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR1 6/4885CNR2 3/4885ROCK2 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback